Preclinical studies for Akkermansia muciniphila

A large body of evidence suggests that Akkermansia muciniphila may help protect against specific metabolic disorders and cardiometabolic risk factors associated with a low-grade inflammatory status.

Indeed, preclinical studies performed in diet-induced obese mice revealed very interesting beneficial effects linked to the daily oral administration of Akkermansia muciniphila. Giving the bacteria to mice every day counteracts the effects of a high-fat diet. The administration of these bacteria is associated with many benefits, such as:

  • a decrease of body weight and fat mass gain
  • a decrease of low-grade inflammation
  • a decrease of glycaemia
  • a decrease of plasma cholesterol, and
  • an improvement of intestinal barrier function due to the increased mucus thickness and production of anti-microbial molecules.(Everard, PNAS 2013)

By restoring a normal mucus layer thickness and optimal barrier function, live bacterium supplementation prevents the development of metabolic endotoxemia. In other words, it prevents the presence of lipopolysaccharides in the blood. By preventing metabolic endotoxemia and low-grade inflammation, supplementation with Akkermansia muciniphila prevents metabolic disorders induced by these triggers. This includes insulin resistance, hepatic inflammation and diabetes.


Furthermore, recent studies have also confirmed the beneficial impact of Akkermansia muciniphila on cardio-metabolic disorders such as atherosclerosis and hypercholesterolemia.

In conclusion, preclinical data have shown that supplementation with Akkermansia muciniphila can:

  • restore gut barrier integrity/permeability;
  • improve glucose metabolism;
  • reduce obesity and related disorders such as glucose intolerance, insulin resistance and hepatic steatosis.
schema 9